U.S. Warns Chinese Exporters Could Be Banned For Poor Drug Products
This article was originally published in PharmAsia News
Chinese companies that export products to the United States could have their drug products barred if they fail to meet U.S. standards. Michael Leavitt, secretary of Health and Human Services, acknowledged during a visit to Beijing his country could not inspect everything imported into the United States, so it must rely on market forces to punish companies and countries that fail to meet product-quality certification standards. In his talks with officials, Leavitt seeks to close a loophole in Chinese regulations that allows ingredients for drugs to be produced without being inspected. (Click here for more - a subscription may be required
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.